IP Library Granted Patent US 6,962,701
Granted Patent B2
US 6,962,701 · App. 10/409,822 · Granted Nov 8, 2005

Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response

Assignee: Medimmune, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,962,701
App. No.
10/409,822
Granted
Nov 8, 2005
Kind
B2
Abstract

Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.

Claims (15)

1. A process for priming the immunogenic activity of a vaccine, comprising:

(a) administering to an animal an effective amount of an antibody specific for one or more of the antigenic determinants characteristic of said vaccine which elicits a protective immune response and whose immunogenic activity is to be primed; and

(b) administering to said animal an effective amount of the vaccine of step (a) wherein said vaccine comprises at least one antigenic determinant for which the antibody of step (a) is not specific.

2. The process of claim 1 wherein step (a) is carried out at least 24 hours before step (b).

3. The process of claim 1 wherein step (a) is carried out at least 48 hours before step (b).

4. The process of claim 1 wherein step (a) is carried out at least 72 hours before step (b).

5. The process of claim 1 wherein step (a) is carried out at least 1 week before step (b).

6. The process of claim 1 wherein the antibody is specific for more than one antigenic determinant present in the vaccine.

7. The process of claim 1 wherein the effective amount of antibody is in the range of 5 to 20 mg/kg of body weight.

8. The process of claim 7 wherein the effective amount of antibody is in the range of 10 to 20 mg/kg body weight.

9. The process of claim 8 wherein the effective amount of antibody is about 15 mg/kg.

10. The process of claim 1 wherein the effective amount of vaccine is between about 5 μg per kg of body weight to about 1 gram per kg body weight.

11. The process of claim 10 wherein the effective amount of vaccine is between about 100 μg per kg of body weight to about 1 gram per kg body weight.

12. The process of claim 10 wherein the amount of vaccine is between about 1 mg per kg of body weight to about 1 gram per kg body weight.

13. The process of claim 10 wherein the effective amount of vaccine is between about 10 mg per kg of body weight to about 1 gram per kg body weight.

Assignments (1)
CHANGE OF NAME Recorded Sep 9, 2008
From: MEDIMMUNE, INC.
To: MEDIMMUNE, LLC
Reel/Frame 021503/0328 →
Continuity (3)
Continuation 0979776000 · Mar 2, 2001
Provisional Application 6018656600 · Mar 2, 2000
Related Publication 20030206907A1 · Nov 6, 2003